What Is Life Expectancy With Primary Immunodeficiency?
At a Glance
Life expectancy with primary immunodeficiency varies widely: many people with well-controlled disease live near-normal lifespans, while severe forms can be life-shortening. The specific diagnosis, early treatment, organ damage, and complications shape each person’s outlook.
Because “primary immunodeficiency” (PI)—also known as an inborn error of immunity (IEI)—is a group of hundreds of different rare disorders, there is no single life expectancy number that applies to everyone. Life expectancy is reduced overall compared to the general population, but it varies drastically depending on the specific condition [1]. Many people with well-controlled forms of PI can achieve near-normal lifespans and lead active lives [2], while some severe or syndromic IEIs remain life-shortening. Your clinical immunologist is the best person to estimate your individual outlook.
What Determines Your Outlook?
Your long-term prognosis depends on a highly individualized set of factors [1][3]:
- Your exact genetic diagnosis and how much residual immune function you have.
- Your age at diagnosis and how quickly effective treatment was started.
- Existing organ damage, particularly bronchiectasis (permanent widening and scarring of the airways in the lungs caused by repeated infections).
- Non-infectious complications, such as an increased risk for malignancy (cancer) [4].
- The presence of autoimmune diseases (where the immune system mistakenly attacks the body’s own tissues) or autoinflammatory diseases (where the immune system causes inappropriate, damaging inflammation without an infection trigger) [3].
The Role of Early Diagnosis
Starting effective treatment quickly helps prevent repeated infections from causing permanent organ damage [5][6]. Today, some severe conditions, like severe combined immunodeficiency (SCID), are detected early through newborn screening. However, newborn screening only looks for a few specific T-cell deficiencies, not the entire spectrum of IEIs. Furthermore, while genetic testing is a powerful tool, results can sometimes be negative or inconclusive. When an underlying immune defect is identified early, it can direct targeted therapies that significantly improve the chance of long-term survival [7][5].
Treatments That Support Longevity
Treatment for PI is not a one-size-fits-all approach. Based on your specific condition, your team may recommend interventions that control risks, or, in specific cases, treatments with curative intent:
- Immunoglobulin (Ig) Replacement Therapy: For patients with specific antibody-production defects, replacing missing antibodies through intravenous (IV) or subcutaneous (under the skin) infusions is a cornerstone of care. Ig therapy lowers infection rates, reduces respiratory symptoms, and improves quality of life [2][8]. However, it does not prevent all infections and cannot reverse established structural lung damage. Treatment requires monitoring, as infusion-related adverse reactions can occur, particularly during initial IV doses [9][10].
- Antimicrobial Prophylaxis: Some individuals require individualized, preventative doses of antibacterial, antifungal, or antiviral medications to ward off specific severe infections [11]. While helpful when combined with timely Ig replacement for certain lung complications [6], daily prophylaxis is not needed for everyone and carries risks like medication side effects, drug interactions, and antimicrobial resistance.
- Hematopoietic Stem Cell Transplantation (HSCT): For selected severe IEIs, HSCT (bone marrow transplant) is used with curative intent to replace the defective immune system [12]. Early diagnosis and HSCT have been shown to improve survival in these high-risk patients [13]. However, this is a high-risk procedure not appropriate for most IEIs. It carries serious potential complications, including severe organ toxicity, graft-versus-host disease, infertility, and transplant-related mortality [14][13].
Living with PI and Urgent Care Planning
Managing an inborn error of immunity requires lifelong, individualized follow-up. Depending on your diagnosis, your team may regularly check your blood counts, lung function, and nutrition, while monitoring for complications [3].
Because infections can progress rapidly, it is vital to have a diagnosis-specific sick-day or fever action plan. Do not wait for a routine appointment if you develop concerning symptoms. Seek urgent medical evaluation if you experience trouble breathing, confusion, severe dehydration, rapidly worsening illness, or a fever that reaches the specific threshold set by your immunology team.
Living with a chronic illness also impacts mental well-being; research notes that self-isolation can lead to depression and anxiety, emphasizing the need for psychosocial support [15]. While living with PI requires individualized precautions and accommodations, with expert multidisciplinary care, many patients are able to pursue school, careers, travel, and family life.
Common questions in this guide
Does primary immunodeficiency always shorten life expectancy?
What factors affect survival with primary immunodeficiency?
Can early diagnosis improve life expectancy with primary immunodeficiency?
Which treatments can help people with primary immunodeficiency live longer?
When should someone with primary immunodeficiency seek urgent medical care?
Related questions
Show more
Get notified when new evidence is published on Primary immunodeficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
[Primary Immunodeficiency: Primary Antibody Disorders in Respiratory Medicine].
Evers G, Thrull M, Wittkowski H, et al.
Pneumologie (Stuttgart, Germany) 2019; (73(2)):94-107 doi:10.1055/s-0043-108085.
PMID: 30759496 - 2
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Wasserman RL, Melamed I, Kobrynski L, et al.
Immunotherapy 2016; (8(10)):1175-86 doi:10.2217/imt-2016-0066.
PMID: 27468136 - 3
Targeted next-generation sequencing for genetic diagnosis of 160 patients with primary immunodeficiency in south China.
Xia Y, He T, Luo Y, et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2018; (29(8)):863-872 doi:10.1111/pai.12976.
PMID: 30152884 - 4
Flow Cytometric Evaluation of Primary Immunodeficiencies.
Boldt A, Bitar M, Sack U
Clinics in laboratory medicine 2017; (37(4)):895-913 doi:10.1016/j.cll.2017.07.013.
PMID: 29128075 - 5
Are inborn errors of immunity being investigated in the pediatric intensive care unit?
de Brito CCM, Bezerra PGM, Lyra PT, de Mello MJG
Jornal de pediatria 2025; (101(3)):388-393 doi:10.1016/j.jped.2024.12.006.
PMID: 39922220 - 6
Pulmonary Manifestations of Inborn Errors of Immunity: Diagnostic and Therapeutic Insights.
Napiorkowska-Baran K, Cofta S, Treichel P, et al.
Life (Basel, Switzerland) 2025; (15(12)) doi:10.3390/life15121838.
PMID: 41465777 - 7
Inborn errors of immunity: A field without frontiers.
Bucciol G, Delafontaine S, Meyts I, Poli C
Immunological reviews 2024; (322(1)):15-27 doi:10.1111/imr.13297.
PMID: 38062988 - 8
[Respiratory manifestations associated with cyclic neutropenia and innate immune deficiency (IgG3 deficiency): a case report].
Rodríguez-Flores DA, Ortiz-Jiménez MDP
Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993) 2025; (72(3)):61-63 doi:10.29262/ram.v72i3.1503.
PMID: 41037692 - 9
Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin.
Esmaeilzadeh H, Askarisarvestani A, Hosseini N, et al.
Clinical immunology (Orlando, Fla.) 2021; (230()):108826 doi:10.1016/j.clim.2021.108826.
PMID: 34418548 - 10
Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: A longitudinal study with a pre-infusion protocol.
Antunes TS, Melo KM, Valente CFC, Tavares FS
Hematology, transfusion and cell therapy 2023; (45(2)):253-258 doi:10.1016/j.htct.2022.06.009.
PMID: 36114118 - 11
Inborn errors of immunity and invasive fungal infections: presentation and management.
Paccoud O, Warris A, Puel A, Lanternier F
Current opinion in infectious diseases 2024; (37(6)):464-473 doi:10.1097/QCO.0000000000001062.
PMID: 39259685 - 12
Haematopoietic stem cell transplantation for inborn errors of immunity: 25-year experience from University of Malaya Medical Centre, Malaysia.
Ariffin H, Ab Rahman S, Jawin V, et al.
Journal of paediatrics and child health 2020; (56(3)):379-383 doi:10.1111/jpc.14621.
PMID: 31479560 - 13
Haematopoietic stem cell transplantation in children with inborn errors of immunity: A single centre experience.
Arman Bilir Ö, Karaatmaca B, Ok Bozkaya İ, et al.
Scandinavian journal of immunology 2025; (101(1)):e13431 doi:10.1111/sji.13431.
PMID: 39781591 - 14
Hematopoietic stem cell transplantation for inborn errors of immunity: 30-year single-center experience.
Dell'Orso G, Bagnasco F, Giardino S, et al.
Frontiers in immunology 2023; (14()):1103080 doi:10.3389/fimmu.2023.1103080.
PMID: 36825011 - 15
Frequency of depression and anxiety in patients with inborn errors of immunity: a cross-sectional study.
Wolff LJ, Witte T, Kahl KG, et al.
BMC psychiatry 2026; (26(1)).
PMID: 42745244
This page is for informational purposes only and does not constitute medical advice about life expectancy with primary immunodeficiency. Your clinical immunologist can interpret your specific diagnosis, complications, and treatment history to discuss your individual outlook.